We are live on ! Find out more
ECM

Endurant Capital Management Portfolio holdings

AUM $17.4M
1-Year Est. Return 7.38%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$380M
AUM Growth
-$34.7M
Cap. Flow
+$1.1M
Cap. Flow %
0.29%
Top 10 Hldgs %
55.07%
Holding
91
New
23
Increased
22
Reduced
16
Closed
28

Top Buys

Rank Stock Value
1
OFIX icon
Orthofix Medical
OFIX
+$13.4M
2
BMY icon
Bristol-Myers Squibb
BMY
+$13.1M
3
CNC icon
Centene
CNC
+$12.1M
4
MCK icon
McKesson
MCK
+$7.93M
5
AVTR icon
Avantor
AVTR
+$6.38M

Top Sells

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$21.3M
2
COR icon
Cencora
COR
+$15.3M
3
XRAY icon
Dentsply Sirona
XRAY
+$9.62M
4
BDX icon
Becton Dickinson
BDX
+$8.66M
5
SIBN icon
SI-BONE Inc
SIBN
+$7.34M

Sector Composition

Rank Sector Weight
1 Healthcare 70.45%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MTEM
51
DELISTED
Molecular Templates, Inc.
MTEM
$1.08M 0.29%
20,949
+3,057
+17% +$135K
CDNA icon
52
CareDx
CDNA
$2.42B
$1.04M 0.27%
+28,048
New +$1.09M
IOVA icon
53
Iovance Biotherapeutics
IOVA
$2.83B
$1.01M 0.27%
60,720
+6,739
+12% +$104K
NTRA icon
54
Natera
NTRA
$46.1B
$1.01M 0.27%
+24,747
New +$1.49M
KZR
55
DELISTED
Kezar Life Sciences
KZR
$988K 0.26%
+5,947
New +$854K
CRL icon
56
Charles River Laboratories
CRL
$12.8B
$939K 0.25%
3,308
-15,278
-82% -$4.71M
PRAX icon
57
Praxis Precision Medicines
PRAX
$10.1B
$811K 0.21%
5,297
-674
-11% -$138K
GOSS icon
58
Gossamer Bio
GOSS
$87M
$596K 0.16%
68,710
-44,950
-40% -$433K
DRIO icon
59
DarioHealth
DRIO
$71.2M
$431K 0.11%
3,689
-860
-19% -$142K
PHAS
60
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$322K 0.08%
243,795
-116,283
-32% -$189K
BDSX icon
61
Biodesix
BDSX
$248M
$221K 0.06%
+6,538
New +$427K
ANGO icon
62
AngioDynamics
ANGO
$649M
– –
-18,125
Closed -$500K
ARAY icon
63
Accuray
ARAY
$34M
– –
-245,764
Closed -$1.17M
ATNM icon
64
Actinium Pharmaceuticals
ATNM
$25M
– –
-66,666
Closed –
ATRC icon
65
AtriCure
ATRC
$2.11B
– –
-24,253
Closed -$1.69M
AUPH icon
66
Aurinia Pharmaceuticals
AUPH
$2.04B
– –
-66,935
Closed -$1.53M
BDX icon
67
Becton Dickinson
BDX
$48.7B
– –
-35,313
Closed -$8.66M
COR icon
68
Cencora
COR
$61.2B
– –
-115,003
Closed -$15.3M
CYH icon
69
Community Health Systems
CYH
$423M
– –
-44,847
Closed -$597K
GDRX icon
70
GoodRx Holdings
GDRX
$1.26B
– –
-68,599
Closed -$2.24M
HAE icon
71
Haemonetics
HAE
$4B
– –
-73,914
Closed -$3.92M
HRTX icon
72
Heron Therapeutics
HRTX
$92.9M
– –
-165,404
Closed -$1.51M
IWM icon
73
PUT
iShares Russell 2000 ETF
IWM
$83B
– –
-12,000
Closed -$2.67M
JNJ icon
74
Johnson & Johnson
JNJ
$625B
– –
-42,762
Closed -$7.32M
KNSA icon
75
Kiniksa Pharmaceuticals
KNSA
$5.93B
– –
-244,125
Closed -$2.87M
1 2
3
4

Similar funds

VAFP
Vahanian & Associates Financial Planning Saratoga Springs, New York $25.3M AUM 39.42% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
SCM
Somerset Capital Management London, United Kingdom $8.12M AUM 21.3% 1-Year Est. Return
FWM
Fiat Wealth Management Wayzata, Minnesota $7.9M AUM
TOPU
Trustees of Princeton University Princeton, New Jersey $7.77M AUM
CCMU
Cheyne Capital Management (UK) London, United Kingdom $27.9M AUM 36.14% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
HSCU
Half Sky Capital (UK) London, United Kingdom $30.5M AUM 67.32% 1-Year Est. Return

Endurant Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Endurant Capital Management held 91 positions worth $380M, down 8.4% from $414M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Endurant Capital Management's Q1 2022 filing shows 23 new, 22 increased, 16 reduced and 28 closed positions. Its largest new stake was Bristol-Myers Squibb: 194,684 shares worth $14.2M. The largest sale was Sanofi, an estimated $21.3M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 72% a quarter earlier, followed by Industrials.

  • Endurant Capital Management's largest Q1 2022 buy was Bristol-Myers Squibb: 194,684 shares worth $14.2M.
  • Endurant Capital Management added most to Orthofix Medical in Q1 2022, an estimated $13.4M increase.
  • Endurant Capital Management's biggest Q1 2022 reduction was SI-BONE Inc, cutting an estimated $7.34M.
  • Endurant Capital Management fully exited Sanofi in Q1 2022, selling an estimated $21.3M.
  • Endurant Capital Management's ten largest holdings make up 55% of its $380M portfolio in Q1 2022.
  • Endurant Capital Management opened 23 new positions and closed 28 in Q1 2022.
  • Endurant Capital Management's portfolio value fell 8.4% quarter-over-quarter to $380M.

Based on Endurant Capital Management's 13F filing for Q1 2022, filed 16 May 2022.